文献速递间质性肺疾病

基于CT的放射组学揭示系统性硬化相关间质性肺病的预后与分子差异

Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis.
PubMed 文献 · Eur Respir J · 2022-05-19

研究在苏黎世(n=90)和奥斯陆(n=66)两个前瞻性SSc-ILD队列中,从常规CT提取1355个放射组学特征,通过无监督聚类识别出两个临床和预后不同的患者群,并构建和外部验证了由26个特征组成的定量放射组学风险评分qRISSc,该评分能准确预测无进展生存期并在多变量Cox回归中显著改善临床风险分层。高qRISSc评分与小鼠博来霉素诱导肺纤维化模型的纤维化通路激活相关。

要点

  • 基于常规CT的放射组学可对SSc-ILD患者进行无监督聚类,识别预后不同的亚群。
  • 26特征组成的qRISSc评分可预测无进展生存期,并在外部验证中改善临床风险分层。
  • 高qRISSc评分与实验性肺纤维化的纤维化通路激活相关,具有生物学可解释性。

核心结论

  • 基于常规CT的放射组学风险分层为SSc-ILD提供补充的表型、临床和预后信息,显著影响临床决策。

研究设计与样本

  • 研究纳入两个独立前瞻性SSc-ILD队列:苏黎世 derivation 队列 n=90,奥斯陆 validation 队列 n=66。
  • 从每个受试者的常规CT图像中定义1355个稳健放射组学特征。
  • 采用无监督聚类识别影像学患者群,并通过监督分析从放射组学特征中推导qRISSc预后评分。
  • 通过与小 鼠博来霉素诱导肺纤维化模型的肺蛋白质组、组织学和基因表达数据相关性,评估qRISSc的生物学基础。

主要发现

  • 放射组学分析识别出两个临床和预后显著不同的SSc-ILD患者群。
  • 由26个特征组成的qRISSc评分在合并队列的多变量Cox回归分析中准确预测无进展生存期,并显著改善临床风险分层参数。
  • 高qRISSc评分(识别进展风险患者)可从人类逆向转化至实验性ILD,并与纤维化通路激活相关。

关键数值与推荐

  • qRISSc由26个放射组学特征组成,为二分类定量风险评分。
  • 在合并队列的多变量Cox回归中,qRISSc显著改善临床风险分层参数(具体数值未报告)。

临床怎么用

  • 利用常规CT图像进行放射组学分析,可辅助SSc-ILD的风险分层和临床决策。
  • qRISSc评分可用于识别进展风险较高的SSc-ILD患者,补充临床风险分层参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiomic features calculated from routine medical images show great potential for personalised medicine in cancer. Patients with systemic sclerosis (SSc), a rare, multiorgan autoimmune disorder, have a similarly poor prognosis due to interstitial lung disease (ILD). Here, our objectives were to explore computed tomography (CT)-based high-dimensional image analysis ("radiomics") for disease characterisation, risk stratification and relaying information on lung pathophysiology in SSc-ILD. METHODS: We investigated two independent, prospectively followed SSc-ILD cohorts (Zurich, derivation cohort, n=90; Oslo, validation cohort, n=66). For every subject, we defined 1355 robust radiomic features from standard-of-care CT images. We performed unsupervised clustering to identify and characterise imaging-based patient clusters. A clinically applicable prognostic quantitative radiomic risk score (qRISSc) for progression-free survival (PFS) was derived from radiomic profiles using supervised analysis. The biological basis of qRISSc was assessed in a cross-species approach by correlation with lung proteomic, histological and gene expression data derived from mice with bleomycin-induced lung fibrosis. RESULTS: Radiomic profiling identified two clinically and prognostically distinct SSc-ILD patient clusters. To evaluate the clinical applicability, we derived and externally validated a binary, quantitative radiomic risk score (qRISSc) composed of 26 features that accurately predicted PFS and significantly improved upon clinical risk stratification parameters in multivariable Cox regression analyses in the pooled cohorts. A high qRISSc score, which identifies patients at risk for progression, was reverse translatable from human to experimental ILD and correlated with fibrotic pathway activation. CONCLUSIONS: Radiomics-based risk stratification using routine CT images provides complementary phenotypic, clinical and prognostic information significantly impacting clinical decision making in SSc-ILD.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Schniering J, Maciukiewicz M, Gabrys HS, et al. Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis. Eur Respir J. 2022. PMID: 34649979. doi:10.1183/13993003.04503-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。